Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and α-synuclein mechanisms.


Journal

Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688

Informations de publication

Date de publication:
06 2019
Historique:
received: 30 11 2018
revised: 02 01 2019
accepted: 21 01 2019
pubmed: 9 4 2019
medline: 14 3 2020
entrez: 9 4 2019
Statut: ppublish

Résumé

Increasing evidence supports an extensive and complex genetic contribution to PD. Previous genome-wide association studies (GWAS) have shed light on the genetic basis of risk for this disease. However, the genetic determinants of PD age at onset are largely unknown. To identify the genetic determinants of PD age at onset. Using genetic data of 28,568 PD cases, we performed a genome-wide association study based on PD age at onset. We estimated that the heritability of PD age at onset attributed to common genetic variation was ∼0.11, lower than the overall heritability of risk for PD (∼0.27), likely, in part, because of the subjective nature of this measure. We found two genome-wide significant association signals, one at SNCA and the other a protein-coding variant in TMEM175, both of which are known PD risk loci and a Bonferroni-corrected significant effect at other known PD risk loci, GBA, INPP5F/BAG3, FAM47E/SCARB2, and MCCC1. Notably, SNCA, TMEM175, SCARB2, BAG3, and GBA have all been shown to be implicated in α-synuclein aggregation pathways. Remarkably, other well-established PD risk loci, such as GCH1 and MAPT, did not show a significant effect on age at onset of PD. Overall, we have performed the largest age at onset of PD genome-wide association studies to date, and our results show that not all PD risk loci influence age at onset with significant differences between risk alleles for age at onset. This provides a compelling picture, both within the context of functional characterization of disease-linked genetic variability and in defining differences between risk alleles for age at onset, or frank risk for disease. © 2019 International Parkinson and Movement Disorder Society.

Sections du résumé

BACKGROUND
Increasing evidence supports an extensive and complex genetic contribution to PD. Previous genome-wide association studies (GWAS) have shed light on the genetic basis of risk for this disease. However, the genetic determinants of PD age at onset are largely unknown.
OBJECTIVES
To identify the genetic determinants of PD age at onset.
METHODS
Using genetic data of 28,568 PD cases, we performed a genome-wide association study based on PD age at onset.
RESULTS
We estimated that the heritability of PD age at onset attributed to common genetic variation was ∼0.11, lower than the overall heritability of risk for PD (∼0.27), likely, in part, because of the subjective nature of this measure. We found two genome-wide significant association signals, one at SNCA and the other a protein-coding variant in TMEM175, both of which are known PD risk loci and a Bonferroni-corrected significant effect at other known PD risk loci, GBA, INPP5F/BAG3, FAM47E/SCARB2, and MCCC1. Notably, SNCA, TMEM175, SCARB2, BAG3, and GBA have all been shown to be implicated in α-synuclein aggregation pathways. Remarkably, other well-established PD risk loci, such as GCH1 and MAPT, did not show a significant effect on age at onset of PD.
CONCLUSIONS
Overall, we have performed the largest age at onset of PD genome-wide association studies to date, and our results show that not all PD risk loci influence age at onset with significant differences between risk alleles for age at onset. This provides a compelling picture, both within the context of functional characterization of disease-linked genetic variability and in defining differences between risk alleles for age at onset, or frank risk for disease. © 2019 International Parkinson and Movement Disorder Society.

Identifiants

pubmed: 30957308
doi: 10.1002/mds.27659
pmc: PMC6579628
mid: NIHMS1017873
doi:

Substances chimiques

SNCA protein, human 0
alpha-Synuclein 0
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 EC 2.7.11.1
GBA protein, human EC 3.2.1.45
Glucosylceramidase EC 3.2.1.45

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

866-875

Subventions

Organisme : Medical Research Council
ID : MR/K01417X/1
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA141668
Pays : United States
Organisme : Medical Research Council
ID : MR/L501542/1
Pays : United Kingdom
Organisme : Intramural NIH HHS
ID : Z01 ES101986
Pays : United States
Organisme : Parkinson's UK
ID : G-0907
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1001799
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N026004/1
Pays : United Kingdom
Organisme : NINDS NIH HHS
ID : R01 NS037167
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA NS003154
Pays : United States
Organisme : Intramural NIH HHS
ID : Z01 AG000949-02
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Parkinson's UK
ID : J-1101
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0701075
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0901254
Pays : United Kingdom
Organisme : NINDS NIH HHS
ID : P50 NS071674
Pays : United States
Organisme : Intramural NIH HHS
ID : Z01 AG000932-01
Pays : United States
Organisme : Intramural NIH HHS
ID : Z01 AG000949
Pays : United States

Informations de copyright

© 2019 International Parkinson and Movement Disorder Society.

Références

Science. 1997 Jun 27;276(5321):2045-7
pubmed: 9197268
J Hum Genet. 2010 Apr;55(4):241-3
pubmed: 20203693
Neurology. 2008 Jun 10;70(24):2277-83
pubmed: 18434642
Science. 2003 Oct 31;302(5646):841
pubmed: 14593171
Cell. 2011 Jul 8;146(1):37-52
pubmed: 21700325
Nat Rev Neurol. 2013 Feb;9(2):106-18
pubmed: 23296339
Autophagy. 2015;11(10):1803-20
pubmed: 26378614
Ageing Res Rev. 2014 Mar;14:19-30
pubmed: 24503004
Proc Natl Acad Sci U S A. 2017 Feb 28;114(9):2389-2394
pubmed: 28193887
Neurology. 2015 Jul 7;85(1):89-95
pubmed: 26062626
Ann Neurol. 2018 Jul;84(1):117-129
pubmed: 30146727
J Neurol Neurosurg Psychiatry. 2009 Aug;80(8):851-7
pubmed: 19246476
Mov Disord. 2013 Aug;28(9):1217-21
pubmed: 23674386
N Engl J Med. 2009 Oct 22;361(17):1651-61
pubmed: 19846850
Hum Mol Genet. 2011 Apr 15;20(8):1478-87
pubmed: 21258085
Neurobiol Aging. 2017 Dec;60:104-115
pubmed: 28941726
Nat Genet. 2015 Mar;47(3):291-5
pubmed: 25642630
Mov Disord. 2015 May;30(6):850-4
pubmed: 25778492
Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S1-6
pubmed: 26350119
Nat Genet. 2012 Mar 18;44(4):369-75, S1-3
pubmed: 22426310
Nature. 2016 May 5;533(7601):95-9
pubmed: 27096366
Hum Mol Genet. 2016 Sep 1;25(17):3849-3862
pubmed: 27402877
Parkinsonism Relat Disord. 2010 May;16(4):237-42
pubmed: 19945904
Int J Epidemiol. 2013 Oct;42(5):1497-501
pubmed: 24159078
Nat Genet. 2009 Dec;41(12):1308-12
pubmed: 19915575
Mov Disord. 2017 Oct;32(10):1432-1438
pubmed: 28639421
JAMA Neurol. 2018 Jan 1;75(1):127-128
pubmed: 29131875
Neurobiol Aging. 2016 Jan;37:209.e1-209.e7
pubmed: 26601739
Lancet Neurol. 2018 Jan;17(1):64-74
pubmed: 29263008
J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):952-7
pubmed: 26701996
JAMA Neurol. 2018 Jan 1;75(1):9-10
pubmed: 29131880
Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15573-8
pubmed: 25316793
Exp Gerontol. 2014 May;53:16-23
pubmed: 24534555
BMC Med Genet. 2009 Sep 22;10:98
pubmed: 19772629
Am J Hum Genet. 2011 Jan 7;88(1):76-82
pubmed: 21167468
Nat Commun. 2014 Aug 26;5:4755
pubmed: 25156829
Nat Commun. 2017 Nov 28;8(1):1826
pubmed: 29184056
Bioinformatics. 2016 May 1;32(9):1423-6
pubmed: 27153000
Ann Neurol. 2008 Jun;63(6):743-50
pubmed: 18571778
Mov Disord. 2015 May;30(6):847-50
pubmed: 25914293
Bioinformatics. 2010 Sep 1;26(17):2190-1
pubmed: 20616382
Neurology. 2015 Mar 3;84(9):880-7
pubmed: 25653295
J Gerontol A Biol Sci Med Sci. 2015 Jan;70(1):110-8
pubmed: 25199915
Nat Genet. 2017 Oct;49(10):1511-1516
pubmed: 28892059
Nat Genet. 2014 Sep;46(9):989-93
pubmed: 25064009
Nat Rev Genet. 2014 May;15(5):335-46
pubmed: 24739678
Neuron. 2016 Jun 15;90(6):1154-1163
pubmed: 27311081
Bioinformatics. 2010 Sep 15;26(18):2336-7
pubmed: 20634204
Hum Mol Genet. 2012 Nov 15;21(22):4996-5009
pubmed: 22892372
J Neurol Neurosurg Psychiatry. 2018 Jul;89(7):702-709
pubmed: 29378790
Neurobiol Dis. 2012 May;46(2):389-92
pubmed: 22349451
J Neurol Neurosurg Psychiatry. 2013 Jun;84(6):666-73
pubmed: 23408064
Ann Neurol. 2015 Apr;77(4):582-91
pubmed: 25773351
J Neurol Neurosurg Psychiatry. 2007 Aug;78(8):819-24
pubmed: 17098842
Neurology. 2009 Jan 27;72(4):310-6
pubmed: 18987351
Digit Health. 2015 Jun 29;1:2055207615592998
pubmed: 29942542

Auteurs

Cornelis Blauwendraat (C)

Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
Neurodegenerative Diseases Research Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.

Karl Heilbron (K)

23andMe, Inc., Mountain View, California, USA.

Costanza L Vallerga (CL)

Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia.

Sara Bandres-Ciga (S)

Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.

Rainer von Coelln (R)

Department of Neurology, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Lasse Pihlstrøm (L)

Department of Neurology, Oslo University Hospital, Oslo, Norway.

Javier Simón-Sánchez (J)

Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.

Claudia Schulte (C)

Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.

Manu Sharma (M)

Centre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry, University of Tubingen, Germany.

Lynne Krohn (L)

Department of Human Genetics, McGill University, Montreal, Quebec, Canada.
Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.

Ari Siitonen (A)

Institute of Clinical Medicine, Department of Neurology, University of Oulu, Oulu, Finland.
Department of Neurology and Medical Research Center, Oulu University Hospital, Oulu, Finland.

Hirotaka Iwaki (H)

Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
The Michael J Fox Foundation for Parkinson's Research, New York, New York, USA.

Hampton Leonard (H)

Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.

Alastair J Noyce (AJ)

Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom.
Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, United Kingdom.

Manuela Tan (M)

Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, United Kingdom.

J Raphael Gibbs (JR)

Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.

Dena G Hernandez (DG)

Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.

Sonja W Scholz (SW)

Neurodegenerative Diseases Research Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.

Joseph Jankovic (J)

Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA.

Lisa M Shulman (LM)

Department of Neurology, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Suzanne Lesage (S)

Inserm U1127, Sorbonne Universités, UPMC Univ Paris 06 UMR S1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France.

Jean-Christophe Corvol (JC)

Inserm U1127, Sorbonne Universités, UPMC Univ Paris 06 UMR S1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France.

Alexis Brice (A)

Inserm U1127, Sorbonne Universités, UPMC Univ Paris 06 UMR S1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France.

Jacobus J van Hilten (JJ)

Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.

Johan Marinus (J)

Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.

Johanna Eerola-Rautio (J)

Department of Neurology, Helsinki University Hospital, and Molecular Neurology, Research Programs Unit, Biomedicum, University of Helsinki, Helsinki, Finland.

Pentti Tienari (P)

Department of Neurology, Helsinki University Hospital, and Molecular Neurology, Research Programs Unit, Biomedicum, University of Helsinki, Helsinki, Finland.

Kari Majamaa (K)

Institute of Clinical Medicine, Department of Neurology, University of Oulu, Oulu, Finland.
Department of Neurology and Medical Research Center, Oulu University Hospital, Oulu, Finland.

Mathias Toft (M)

Department of Neurology, Oslo University Hospital, Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Donald G Grosset (DG)

Department of Neurology, Institute of Neurological Sciences, Queen Elizabeth University Hospital, Glasgow, United Kingdom.
Institute of Neuroscience & Psychology, University of Glasgow, Glasgow, United Kingdom.

Thomas Gasser (T)

Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.

Peter Heutink (P)

Department for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.

Joshua M Shulman (JM)

Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA.
Departments of Molecular & Human Genetics and Neuroscience, Baylor College of Medicine, Houston, Texas, USA.
Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, Texas, USA.

Nicolas Wood (N)

Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, United Kingdom.

John Hardy (J)

Department of Neurodegenerative Diseases, UCL Queen Square Institute of Neurology, London, United Kingdom.

Huw R Morris (HR)

Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, United Kingdom.

David A Hinds (DA)

23andMe, Inc., Mountain View, California, USA.

Jacob Gratten (J)

Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia.
Mater Research, Translational Research Institute, Brisbane, Queensland, Australia.

Peter M Visscher (PM)

Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia.
Queensland Brain Institute, The University of Queensland, Brisbane, Australia.

Ziv Gan-Or (Z)

Department of Human Genetics, McGill University, Montreal, Quebec, Canada.
Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.
Department of Neurology & Neurosurgery, McGill University, Montreal, Quebec, Canada.

Mike A Nalls (MA)

Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.
Data Tecnica International, Glen Echo, Maryland, USA.

Andrew B Singleton (AB)

Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH